Skip to main content


Figure 5 | Molecular Cancer

Figure 5

From: High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde

Figure 5

Targeted disruption of the c-Myc gene reduced the responsiveness to TRAIL and the expression of DR5 in PC3-MM2 cells. (A) PC3-MM2 cells were transfected with siRNA against c-Myc or scrambled siRNA as a control. After 48 h, the transfectants were treated with TRAIL (2 or 10 ng/ml) for 6 h, and the percentage of apoptotic cells was determined using Annexin V staining and flow cytometry (left). In addition, the transfectants were treated with graded single doses of TRAIL (1~10 ng/ml), and percentage of cell survival was determined after 96 h incubation using the MTT assay (right). Data represent the mean ± SE of triplicate experiments. *p < 0.05, **p < 0.01, ***p < 0.001. (B) The transfected cells incubated with anti-DR5 antibody (1:100), and subsequently labeled with FITC-conjugated secondary antibodies (1:200) to determine the surface expression of DR5. Mouse IgG was also used as an isotype control. The shaded and unshaded peaks correspond to control and specific staining, respectively.

Back to article page